The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...
Mammogram providers are now federally required to tell their patients about their breast density. The new U.S. Food and Drug ...
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.